Pure Global
NCT06375304

The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study

Antiretroviral Speed Access Program Switch Study (The ASAP Switch Study) - A Pilot Study to Switch ART-experienced and Newly-referred Migrant People With HIV to B/F/TAF
McGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
HIV Infections
Drug/Device/Intervention
B/F/TAF
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Location
Montréal, Canada
Timeline & enrollment
Phase
Phase 4
Start date
May 01, 2024
End date
May 01, 2027
Enrollment
50 participants
Primary outcome

Feasibility of the switch,Acceptability,acceptability of the regimen,Acceptability of the intervention,Fidelity

Summary

This project builds on our experience with the ASAP Study (McGill University Health Centre
 research ethics board: MP-37-2020-4911). The goal of this study is to better understand the
 experience of migrant people with Human Immunodeficiency Virus (HIV) of having their
 treatment switched to Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). In other
 words, the investigators want to evaluate how feasible and acceptable this switch is, and how
 participants will take B/F/TAF (fidelity) and remain on it. The investigators also want to
 know more about migrant people with HIV's experience of care; namely, how often they see
 their HIV specialist or other healthcare professionals, and their healthcare coverage (the
 type of insurance that they have).

ICD-10 classifications
HIV disease resulting in other viral infectionsHIV disease resulting in other bacterial infectionsHIV disease resulting in multiple infectionsAcute HIV infection syndromeHIV disease resulting in other infectious and parasitic diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06375304
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06375304 through Pure Global AI's free database. This Phase 4 trial is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre and is currently Not yet recruiting. The study focuses on HIV Infections. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.